Clinical Trial Update: mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for mFOLFOX7 plus Camrelizumab and Apatinib in non-resectable hepatocellular carcinoma beyond Milan criteria, currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)
• mFOLFOX7 (modified FOLFOX7) regimen

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Hepatocellular Carcinoma Non-resectable | Phase 2 | Status: RECRUITING